Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg; Combination Product · Drug
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 4 Years and older
Enrollment: 3,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 139 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Conditions: Status Asthmaticus, Asthma
Interventions: Montelukast, Sterile water; Drug · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 5 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more

Conditions: Asthma, Lung Diseases
Interventions: Albuterol, Colchicine, Adrenal Cortex Hormones, Adrenergic-Beta Agonists; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2008
U.S. locations: 7
States / cities: La Jolla, California • San Francisco, California • Denver, Colorado + 4 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Spirometry test, Levalbuterol; Device · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Altitude Edema
Interventions: Advair HFA, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Asthma
Interventions: AccuPAP, Albuterol and Ipratropium Continuous Nebulizer; Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma
Interventions: Albuterol and budesonide inhalation aerosol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: North Hollywood, California • Walnut Creek, California • Louisville, Kentucky + 8 more

Conditions: Asthma
Interventions: Levalbuterol, Levalbuterol UDV TID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 46
States / cities: Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 54
States / cities: Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more

Conditions: Asthma
Interventions: Advair Diskus100/50 µg, Flovent Diskus 100 µg, Methacholine Chloride, Albuterol; Drug
Lead sponsor: University of Florida; Other
Eligibility: 4 Years to 11 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Heathy Participants
Interventions: Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: Asthma
Interventions: levalbuterol tartrate HFA inhalation aerosol, placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: St. Petersburg, Florida • DeKalb, Illinois • Nicholasville, Kentucky + 12 more

Conditions: Asthma
Interventions: Albuterol Sulfate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more

Conditions: Asthma
Interventions: Albuterol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Little Rock, Arkansas • Huntington Beach, California • San Jose, California + 11 more

Conditions: Asthma
Interventions: Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 75
States / cities: Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Asthma
Interventions: AS MDI, Proventil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol + Fluticasone Furoate, Placebo, Albuterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Status Asthmaticus
Interventions: Helium-oxygen-driven albuterol nebulizer, Oxygen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 24 Months to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions: Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation); Combination Product
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Montelukast With Status Asthmaticus, Ages 2-5

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Asthma Clinical Research Network (ACRN)

COPD Assessment and Management Bundle Versus Usual Care

Advair HFA in Healthy and HAPE Predisposed Subjects

Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Dose-Response of Salmeterol in Children

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals